- Home
- BOOT vs RNA Comparison
BOOT vs RNA Comparison
Compare BOOT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | RNA |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 227.6M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BOOT | RNA |
|---|---|---|
| Price | $162.20 | $13.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $212.83 | $69.26 |
| AVG Volume (30 Days) | 417.3K | ★ 2.4M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.50 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.88 | $88.12 |
| Revenue Next Year | $13.88 | $18.11 |
| P/E Ratio | $28.31 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $86.17 | $13.06 |
| 52 Week High | $210.25 | $73.06 |
Technical Indicators
Market Signals| Indicator | BOOT | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 27.16 | 5.62 |
| Support Level | $148.84 | $13.06 |
| Resistance Level | $171.05 | $72.52 |
| Average True Range (ATR) | 7.03 | 0.99 |
| MACD | -3.05 | -2.13 |
| Stochastic Oscillator | 0.00 | 1.21 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.